🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

Predicting High-Flow Nasal Cannula Failure in Acute Hypoxemic Respiratory Failure Using Metabolomics and Clinical Data

Recruitingn/aAges 18 Years - anyAllHospital del Mar Research Institute (IMIM)
NCT07607080 on ClinicalTrials.gov ↗
💬

In plain words

What the trial is, and whether it could suit you

The goal of this observational study is to determine whether metabolomic profiles combined with clinical data can predict high-flow nasal cannula (HFNC) failure and help optimize respiratory support in adult patients with acute hypoxemic respiratory failure (AHRF). The main questions it aims to answer are: Can metabolomic biomarkers identify patients at higher risk of HFNC failure? Does combining metabolomic and clinical data improve the prediction of respiratory support escalation and clinical outcomes? Participants will: Receive standard HFNC treatment according to clinical practice. Undergo collection of clinical, physiological, and laboratory data. Provide blood samples for metabolomic analysis during respiratory support.

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
📋 Eligibility rules (as published)
Inclusion Criteria: * Adult patients (≥18 years old). * Admission to the intensive care unit (ICU) with acute hypoxemic respiratory failure (AHRF). * Treatment with high-flow nasal cannula (HFNC) as the initial respiratory support strategy. * Inclusion within the first 24 hours after HFNC initiation. * Provision of informed consent by the patient or legally authorized representative. Exclusion Criteria: * Age \<18 years. * Active do-not-resuscitate (DNR) orders or limitation of therapeutic effort. * Refusal or inability to provide informed consent. * Previous invasive mechanical ventilation before study inclusion.
💊

What it tests

  • Not listed
📍

Where

1 site
Hospital del Mar
Barcelona, Spain
🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy